AstraZeneca (AZN) RNS Announcements

Add to Alert list
Date Time Source Announcement
08 Nov 2018 07:00 AM
RNS
AZN: Year-to-Date and Q3 2018 Results
06 Nov 2018 07:00 AM
RNS
Divestment of rights to Covis Pharma
01 Nov 2018 03:00 PM
RNS
Total Voting Rights
31 Oct 2018 09:45 AM
RNS
Additional financial information-Grünenthal deal
30 Oct 2018 07:00 AM
RNS
Grünenthal Agreement for rights to Nexium, Vimovo
23 Oct 2018 07:00 AM
RNS
AstraZeneca Extends Innate Pharma Collaboration
22 Oct 2018 07:00 AM
RNS
Lynparza shows 70% reduction in PFS ovarian cancer
19 Oct 2018 01:09 PM
RNS
CHMP positive opinion Bevespi Aerosphere
16 Oct 2018 07:00 AM
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
01 Oct 2018 03:00 PM
RNS
Total Voting Rights
01 Oct 2018 07:00 AM
RNS
Atacand Agreement with Cheplapharm Completed
28 Sep 2018 04:00 PM
RNS
Previous Announcement Regarding Appointment Of NED
25 Sep 2018 01:15 PM
RNS
Overall survival data for Imfinzi: Stage III NSCLC
24 Sep 2018 04:10 PM
RNS
EMA approves AZ's Imfinzi for Stage III NSCLC
24 Sep 2018 07:00 AM
RNS
Farxiga gets positive result in DECLARE-TIMI 58
14 Sep 2018 07:00 AM
RNS
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07 Sep 2018 07:00 AM
RNS
Tezepelumab FDA Breakthrough Therapy Designation
06 Sep 2018 07:00 AM
RNS
Directorate Change
03 Sep 2018 03:00 PM
RNS
Total Voting Rights
31 Aug 2018 07:00 AM
RNS
AstraZeneca Update on Anifrolumab in SLE
30 Aug 2018 07:00 AM
RNS
EC approves Bydureon BCise device for T2 diabetes
23 Aug 2018 07:00 AM
RNS
AstraZeneca PIIIb trial update for Bevespi in COPD
21 Aug 2018 07:00 AM
RNS
AZ's Tagrisso approved in Japan for 1st-line NSCLC
15 Aug 2018 07:00 AM
RNS
AstraZeneca prices a $3bn bond issue
03 Aug 2018 07:00 AM
RNS
EMA grants OD for selumetinib in NF1
01 Aug 2018 03:00 PM
RNS
Total Voting Rights
27 Jul 2018 02:00 PM
RNS
CHMP recommends Imfinzi for Stage III nsclc
26 Jul 2018 07:00 AM
RNS
AZN: H1 2018 Results
24 Jul 2018 07:00 AM
RNS
Atacand to be divested to Cheplapharm in Europe
18 Jul 2018 12:00 PM
RNS
Holding(s) in Company
02 Jul 2018 03:00 PM
RNS
Total Voting Rights
02 Jul 2018 07:00 AM
RNS
Imfinzi approved in Japan for Stage III nsclc
02 Jul 2018 07:00 AM
RNS
Lynparza approved in Japan for BRCAm breast cancer
29 Jun 2018 03:00 PM
RNS
Bydureon receives positive CHMP opinion for BCise
28 Jun 2018 01:30 PM
RNS
AZ and Luye Pharma complete agreement for Seroquel
27 Jun 2018 07:00 AM
RNS
Lynparza: significant PFS 1st-line ovarian cancer
26 Jun 2018 07:00 AM
RNS
Board Committee Changes
22 Jun 2018 07:00 AM
RNS
Publication of a Prospectus
12 Jun 2018 07:00 AM
RNS
Update: lanabecestat Phase III Alzheimer's trials
08 Jun 2018 05:30 PM
RNS
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
08 Jun 2018 07:00 AM
RNS
Director Declaration
01 Jun 2018 03:00 PM
RNS
Block listing Interim Review
01 Jun 2018 03:00 PM
RNS
Total Voting Rights
01 Jun 2018 11:00 AM
RNS
Director Declaration
30 May 2018 07:00 AM
RNS
Update on TERRANOVA PIII trial for Fasenra in COPD
25 May 2018 07:00 AM
RNS
AZ's Imfinzi: significant OS in Stage III nsclc
21 May 2018 07:00 AM
RNS
AZ regulatory submission in Japan for Forxiga
21 May 2018 07:00 AM
RNS
US FDA approves Lokelma for adult hyperkalaemia
18 May 2018 05:30 PM
RNS
Result of AGM
18 May 2018 07:00 AM
RNS
AZN: Q1 2018 Results
AstraZeneca PLC, known as AZN on the London Stock Exchange (LSE), is an Anglo-Swedish multinational pharmaceutical and biotechnology company. Founded on April 6, 1999, AstraZeneca was formed through the merger of the Swedish Astra AB and the British Zeneca Group. The company's roots trace back to 1913, when Astra AB was established by a group of doctors and apothecaries in Södertälje, Sweden. Throughout the twentieth century, AstraZeneca grew into one of the largest pharmaceutical companies in the world. It has made numerous corporate acquisitions, including Cambridge Antibody Technology (in 2006), MedImmune (in 2007), Spirogen (in 2013) and Definiens (by MedImmune in 2014). Today, AstraZeneca operates in over 100 countries and employs around 83,000 people. As a member of the LSEG, AZN continues to shape the global healthcare landscape. The company is committed to defeating diseases that impact people's health.
UK 100